Global Eylea Market Analysis (2024-2030).pdf

Apelo Consulting has released a report on “Global Eylea Market (By Disorder, Product, End User, Region), Company profiles and Market Dynamics – Forecast to 2030"

1. 2024-2030
GLOBAL EYLEA MARKET ANALYSIS
Comprehensive Market Overview | Growth Drivers | Segmentation | Regional
Insights | Future Outlook
Prepared by Apelo Consulting
October 2025
1Global Eylea Market Analysis Apelo Consulting

2. EXECUTIVE SUMMARY ~7% CAGR
The global Eylea market was valued at USD 9,714 Million in
2024, projected to reach USD 14,545 Million by 2030.
Robust growth driven by rising retinal diseases, aging
demographics, and innovative treatment formats.
Widespread adoption across all regions and key end
user segments.
Backed by strong clinical evidence and robust safety
profile.
Key Growth Rate
2024-2030 Forecast Period
2Global Eylea Market Analysis | Executive Summary Apelo Consulting

3. Eylea (aflibercept) is a potent anti-VEGF therapy that
inhibits abnormal blood vessel growth in the retina
Administered via intravitreal injection by
ophthalmologists
Redefined standards for retinal disease management
over the past decade
Backed by robust clinical evidence with a consistent
safety profile
Key Benefit
Improves vision and reduces risk of blindness in
patients with retinal diseases
3Global Eylea Market Analysis | What is Eylea? Apelo Consulting
What is Eylea? (Aflibercept)
Wet Age-related Macular Degeneration (AMD)
Leading cause of vision loss in adults over 50
Diabetic Macular Edema (DME)
Complication of diabetes affecting vision
Diabetic Retinopathy (DR)
Progressive damage to retina due to diabetes
Retinal Vein Occlusion (RVO)
Blockage of veins carrying blood from retina
Myopic Choroidal Neovascularization (mCNV)
Complication of severe near-sightedness
Primary Medical Applications:

4. Aging Population
Rising global aging population fueling
increased incidence of age-related
macular degeneration and other retinal
disorders.
Market Growth Drivers
Diabetes Prevalence
Escalating prevalence of diabetes
worldwide, leading to higher rates of
diabetic eye conditions requiring
treatment.
Safety Profile
Strong clinical evidence and consistent
safety profile earning trust among
ophthalmologists and patients alike.
Product Innovation
Major companies focusing on new product launches and delivery
formats to expand treatment options and meet evolving patient
needs.
Healthcare Infrastructure
Advancement in healthcare infrastructure and greater
screening/diagnosis capabilities across developed and emerging
markets.
Projected Market Growth from 2024-2030
USD 9,714M → USD 14,545M
Representing ~7% CAGR
4Global Eylea Market Analysis | Market Growth Drivers Apelo Consulting

5. Wet Age-related Macular Degeneration (AMD)
Market leader in 2024
Over 200 million affected globally, projected to reach 300 million by 2040
Market Segmentation by Disorder
Diabetic Macular Edema (DME)
Growing segment driven by diabetes prevalence
Approximately 21 million people affected globally
Myopic Choroidal Neovascularization (mCNV)
Low double-digit market share in 2024
Rising prevalence in East Asia with improved diagnosis
Other indications include Diabetic Retinopathy (DR) and Retinal
Vein Occlusion (RVO)
Key Insight
AMD prevalence is increasing due to aging global population, driving
market growth for Eylea through 2030
5Global Eylea Market Analysis | Market Segmentation by Disorder Apelo Consulting

6. Largest market share in 2024
Favored for convenience and streamlined dispensing
Growing preference among healthcare providers
Reduces preparation time and dosing errors
Prefilled Syringe Package
Segmentation: By Product Type
Popular in cost-sensitive markets
Compatible with standard intravitreal administration
Preferred in regions with less advanced healthcare
infrastructure
More economical option where cost constraints are critical
Vial Package
Manufacturers expanding production facilities in emerging
markets
Supply chain optimization reducing costs and improving
efficiency
Regional adaptations based on healthcare infrastructure
and cost considerations
Market Expansion Trends
6Global Eylea Market Analysis | Product Type Segmentation Apelo Consulting

7. Hospitals
Largest market segment due to advanced ophthalmic
care infrastructure
Well-established specialized eye care units with
experienced retinal specialists
On-site pharmacy services creating ideal setting for
Eylea administration
Retail Pharmacies
Others segment includes:
Specialty clinics, ambulatory surgical centers, and ophthalmology
practice
Segmentation: By End User
Fast-growing segment driven by decentralized care
models
Increasing patient need for convenient treatment access
Rise in prefilled syringes format optimized for pharmacy
dispensing
7Global Eylea Market Analysis | End User Segmentation Apelo Consulting

8. North America - Market leader in 2024, driven by robust
healthcare infrastructure, supportive reimbursement
policies, and high awareness of anti-VEGF therapy.
Europe - ~25% market share, backed by advanced
therapeutics adoption and favorable policies in Germany,
France, and the UK.
Asia Pacific - Fastest growth potential, driven by increasing
diabetes prevalence and aging populations, especially in
China, Japan, and India.
Latin America, Middle East & Africa - Emerging
opportunities with expanding healthcare access.
Regional Growth Spotlight
Surging diabetes rates and improving healthcare infrastructure
Regional Market Analysis
8Global Eylea Market Analysis | Regional Market Analysis Apelo Consulting
Asia Pacific: Highest CAGR

9. AMD Patients
Globally (2024)
Increasing diagnosis rates, emerging markets expansion, and new
treatment formats driving future market growth
Growth Opportunities
Key Market Highlights
Wet AMD dominance: Over 200 million people
affected globally, projected to reach 300 million
by 2040.
Diabetic Macular Edema: Affects approximately
21 million people worldwide, driving significant
market growth.
Prefilled syringes: Captured highest market share
in 2024, expanding into emerging markets.
Hospitals: Dominant end-user segment with
specialized ophthalmic care infrastructure.
200 M+
DME Patients
Worldwide
21 M
9Global Eylea Market Analysis | Key Market Highlights Apelo Consulting

10. Challenges
Cost pressures in healthcare systems worldwide
Competition from biosimilars and alternative therapies
Limited access in low-resource settings
Growth Drivers
Aging global population driving increased incidence of age-
related eye disorders
Rising diabetes prevalence, particularly in developing
economies
Enhanced healthcare infrastructure and reimbursement
policies
Increased disease awareness and early screening
programs
Market Dynamics & Future Outlook
Future Outlook (2024-2030)
Strategic Forecast
Continued expansion into new therapeutic
indications
Regional production scale-up in emerging markets
Innovation in delivery formats and treatment
regimens
Greater accessibility through improved distribution
networks
10Global Eylea Market Analysis | Market Dynamics & Future Outlook Apelo Consulting

11. THANK YOU www.apeloconsulting.com